In today’s briefing:
- Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for March
- Hollysys (HOLI US): 8th Feb Shareholder Vote. Dazheng Fails The Sniff Test
- Crypto Moves #9 – Is It Too Obvious That 2024 is the Year of Crypto?
- China’s Role as Commodity Importer & The Problem that Emerges for the Soybean Complex
- Aspira Women’s Health, Inc. – Aspira Women’s Health Hosts R&D Day
Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for March
- At 82 index constituents currently, we expect the index committee to progress towards reaching 100 constituents. We are (highly) unlikely to reach the target this calendar year though.
- We highlight nine stocks that have a decent chance at being added to the index over the next couple of rebalances. All companies are profitable and meet inclusion requirements.
- The market consultation on proposed changes to the Hang Seng Industry Classification System (HSICS) could lead to more inclusions from the Information Technology sector from the June rebalance.
Hollysys (HOLI US): 8th Feb Shareholder Vote. Dazheng Fails The Sniff Test
- Hollysys Automation Technologies (HOLI US) has announced that an EGM is scheduled for February 8th to vote on the merger agreement with Ascendent Capital Partners.
- The Offer price remains at US$26.50/ADS. The shareholder approval required is simple majority. Regulatory approvals include NDRC, MoC and SAFE. Maybe a national security review.
- And the Dazheng consortium? Apparently insufficient information as to its financing sources and consortium structure ruled it out. Separately, the SGM to spill the board has now been called off.
Crypto Moves #9 – Is It Too Obvious That 2024 is the Year of Crypto?
- Everyone is buzzing with anticipation, predicting a highly favorable year for crypto.
- The general sentiment in the market suggests that 2024 will be a memorable year, drawing parallels to the positive environments witnessed in 2017 and 2021.
- The crypto landscape was overshadowed by the dramatic collapse of FTX in November 2022, making 2022 end on a rather bleak note.
China’s Role as Commodity Importer & The Problem that Emerges for the Soybean Complex
- We all know about China’s importance in global trade as it is the single most important importer of many key commodities and raw materials.
- This great chart by S&P Global highlights this once again.
- Meanwhile, this importance could at least top out over the next couple of years – as the demographic problem really hits the country.
Aspira Women’s Health, Inc. – Aspira Women’s Health Hosts R&D Day
- Aspira Women’s Health hosted an R&D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.
- CEO Nicole Sandford led the discussion, and was joined by Chief Scientific Officer Dr. Jody Berry, PhD, and one of Aspira’s medical advisors and research partners, Dr. Kevin Elias, MD.
- Aspira also discussed the domestic market potential for both ovarian cancer and endometriosis products, which it estimates is more than $1.5 billion.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
